Verified Supplement Data Primary-sourced

CLA (Conjugated Linoleic Acid): The Honest Guide to a Modest Fat-Loss Supplement

By Erin Rose · Updated · Methodology

Educational overview — not medical advice. CLA is a "landmine" YMYL category: the fat-loss effect is smaller than marketing implies, and several trials found a real metabolic-risk trade-off in the population most likely to buy it — see the safety section below. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

CLA is the textbook animal-vs-human-gap supplement. In rodents and livestock, CLA produces dramatic, reproducible fat loss. In humans, two meta-analyses land on a small, plateauing effect — about 0.09 kg/week at the 3.2 g/day median dose (Whigham 2007), not "melts fat." Worse: several trials found CLA — especially the t10,c12 isomer — worsens insulin sensitivity and lowers HDL in the obese/metabolic-syndrome population most likely to buy it (Risérus 2002). Two rare case reports document severe hepatotoxicity. The honest verdict: a small, plateauing benefit paired with a real metabolic-risk question mark — not a proven fat burner.

As an Amazon Associate we earn from qualifying purchases. Ranked by disclosed active CLA and cost, never commissions.

Start here

What CLA is (and the gap between animal and human data)

Conjugated linoleic acid is a group of naturally occurring fatty-acid isomers found in beef and dairy, sold as a supplement in concentrated form — usually a roughly 50:50 blend of the cis-9,trans-11 and trans-10,cis-12 isomers derived from safflower oil. Its reputation as a fat-loss supplement comes almost entirely from animal and cell studies, where CLA (especially the trans-10,cis-12 isomer) produces dramatic, reproducible reductions in body fat in mice and livestock. That result never should have been marketed straight onto a human supplement label — and the human trials bear that out. Two independent meta-analyses of human randomized controlled trials found a real but small effect: Whigham 2007 pooled 18 RCTs and found a dose-response fat-loss effect that reached about 0.09 kg/week versus placebo at the 3.2 g/day median dose (P<0.001), linear to about 6 months and then plateauing toward an asymptote by 2 years. Onakpoya 2012 pooled 7 longer-term RCTs and found a statistically significant but small 1.33 kg fat-mass difference favoring CLA, concluding in its own words that "the magnitude of these effects is small, and the clinical relevance is uncertain."

Does it work? (the honest short version)

Modestly, and with a catch most marketing leaves out. The fat-loss signal is real and appears across multiple independent trials and two meta-analyses — it is not nothing. But it is small (roughly a pound every few weeks at best, per Whigham's math) and it plateaus rather than compounding, which means CLA is not a substitute for the diet and exercise changes that produce much larger results. The catch: several well-controlled trials found CLA supplementation — particularly the isolated trans-10,cis-12 isomer, but in at least one trial also a standard 50:50 blend — worsened insulin sensitivity and raised fasting glucose, measured directly in obese, metabolic-syndrome, or type-2-diabetic participants (Risérus 2002; Moloney 2004) — and lowered HDL cholesterol in Risérus 2002 (though Moloney 2004 saw HDL rise, so the HDL signal isn't universal). That is precisely the population a "lose belly fat" product markets to. See the full trial-by-trial breakdown on does CLA actually work.

The one-line takeaway CLA produces a small, plateauing fat-loss effect in humans (about 0.09 kg/week at best) — nothing like the dramatic animal data — and several trials found it worsens insulin resistance and lowers HDL in the exact population most likely to buy it. Two rare case reports document severe hepatotoxicity. This is not a proven fat burner, and for most people — especially anyone with insulin resistance, prediabetes, or type 2 diabetes — it's arguably not worth the trade-off.

The buying and safety problem

Retail CLA products routinely under-dose relative to the ~3.2 g/day studied median: many softgels are 800-1,250 mg, so reaching a trial-relevant dose takes 3-4+ softgels a day, not the "take 1" a label photo implies — see the real cost-per-gram math on best CLA. On safety, the headline risks are insulin resistance/impaired glucose metabolism, reduced HDL cholesterol, and increased inflammation/oxidative stress — all measured directly in human trials, not theoretical — plus common GI upset and two rare but severe hepatotoxicity case reports (one requiring a liver transplant). Anyone with diabetes, prediabetes, or metabolic syndrome has the most reason for caution, precisely because that is the population the adverse glucose/insulin signal was measured in.

Frequently asked questions

Does CLA actually help you lose fat?

A little, and it plateaus. Two meta-analyses found small effects: ~0.09 kg/week at the 3.2 g/day median dose (Whigham 2007), and ~1.33 kg fat mass over 6+ months with "uncertain" clinical relevance (Onakpoya 2012). Not a dramatic fat burner.

Is CLA safe?

Mostly at typical doses, but several trials found it worsens insulin sensitivity and lowers HDL in obese/metabolic-syndrome/diabetic populations — the exact buyers most likely to want it. Two rare case reports document severe hepatotoxicity.

How much CLA should I take?

3.2 g/day is the meta-analysis median dose; trial range 1.7–6.8 g/day; no added benefit found above 3.4 g/day. Many retail softgels under-dose relative to this — check the label math.

What's the difference between CLA isomers?

Most retail CLA is a ~50:50 c9,t11:t10,c12 blend. The t10,c12 isomer is tied to the insulin-resistance signal, but a 50:50 blend also worsened glucose/insulin in one T2D trial — the blend isn't automatically risk-free.

Related guides

  • MCT Oil — another fat-loss/body-composition-adjacent supplement with its own honest "does it work" reckoning
  • L-Carnitine — a similarly modest, form-specific fat-loss and metabolic supplement
  • Berberine — the natural cross-link from CLA's insulin-resistance signal; a blood-sugar-marketed supplement with its own trade-offs
  • Glucomannan — a fiber-based weight-management supplement with a different, appetite-based mechanism
  • Chromium — another blood-sugar-marketed mineral worth comparing against CLA's glucose-metabolism trade-off
  • Alpha-Lipoic Acid — an antioxidant that contrasts with CLA's oxidative-stress signal

Sources

  1. Whigham LD, Watras AC, Schoeller DA. "Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans." Am J Clin Nutr. 2007. PMID: 17490954
  2. Onakpoya IJ, Posadzki PP, Watson LK, Davies LA, Ernst E. "The efficacy of long-term conjugated linoleic acid (CLA) supplementation on body composition in overweight and obese individuals: a systematic review and meta-analysis of randomized clinical trials." Eur J Nutr. 2012. PMID: 21990002
  3. Risérus U, Arner P, Brismar K, Vessby B. "Treatment with dietary trans10cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome." Diabetes Care. 2002. PMID: 12196420
  4. Moloney F, Yeow TP, Mullen A, Nolan JJ, Roche HM. "Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus." Am J Clin Nutr. 2004. PMID: 15447895
  5. Full product dataset: /cla/cost-by-brand.json (CC BY 4.0).